EZETIMIBE- ezetimibe tablet

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

EZETIMIBE (UNII: EOR26LQQ24) (EZETIMIBE - UNII:EOR26LQQ24)

제공처:

A-S Medication Solutions

INN (국제 이름):

EZETIMIBE

구성:

EZETIMIBE 10 mg

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Monotherapy Ezetimibe, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) Ezetimibe, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LD

제품 요약:

Product: 50090-2717 NDC: 50090-2717-0 30 TABLET in a BOTTLE

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

EZETIMIBE- EZETIMIBE TABLET
A-S MEDICATION SOLUTIONS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
EZETIMIBE SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR EZETIMIBE.
INITIAL U.S. APPROVAL: 2002
RECENT MAJOR CHANGES
Indications and Usage
•
Dosage and Administration
•
INDICATIONS AND USAGE
Ezetimibe is an inhibitor of intestinal cholesterol (and related
phytosterol) absorption indicated as an adjunct to diet to:
•
•
•
•
Limitations of Use (1.4)
•
•
DOSAGE AND ADMINISTRATION
•
•
DOSAGE FORMS AND STRENGTHS
•
CONTRAINDICATIONS
•
•
•
•
•
WARNINGS AND PRECAUTIONS
•
•
•
Addition of non-HDL lipid parameter to Monotherapy and Combination
therapy (1.1) 07/2011
Patients with Renal Impairment (2.5) 01/2012
Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with
primary hyperlipidemia, alone or in
combination with an HMG-CoA reductase inhibitor (statin) (1.1)
Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with
mixed hyperlipidemia in combination with
fenofibrate (1.1)
Reduce elevated total-C and LDL-C in patients with homozygous familial
hypercholesterolemia (HoFH), in
combination with atorvastatin or simvastatin (1.2)
Reduce elevated sitosterol and campesterol in patients with homozygous
sitosterolemia (phytosterolemia) (1.3)
The effect of ezetimibe on cardiovascular morbidity and mortality has
not been determined.
Ezetimibe has not been studied in Fredrickson Type I, III, IV, and V
dyslipidemias.
One 10-mg tablet once daily, with or without food (2.1)
Dosing of ezetimibe should occur either ≥2 hours before or ≥4
hours after administration of a bile acid sequestrant.
(2.3, 7.4)
Tablets: 10 mg (3)
Statin contraindications apply when ezetimibe is used with a statin:
Active liver disease, which may include unexplained persistent
elevations in hepatic transaminase levels (4, 5.2)
Women who are pregnant or may become pregnant (4, 8.1)
Nursing mothers (4, 8.3)
Known hypersensi